E Fund CSI Innovative Drugs ETF(516080) falls 1.55%, with a share increase of 23.00 million units over the past 2 weeks

NewTimeSpace (newtimespace.com) News, as of 11:10 on June 16, 2026, E Fund Innovative Drug ETF (516080) fell 1.55%, with the latest price at 0.57 yuan. Over a longer time frame, as of June 15, 2026, the ETF accumulated a gain of 3.38% over the past week.

In terms of liquidity, E Fund Innovative Drug ETF recorded an intraday turnover rate of 1.69% and a trading volume of 28.0298 million yuan. Over a longer time frame, as of June 15, the ETF's average daily trading volume over the past week reached 69.0304 million yuan, ranking in the top 3 among comparable funds.

In terms of scale, E Fund Innovative Drug ETF saw a significant increase of 464 million yuan in scale over the past three months, with the new scale increase ranking 1/7 among comparable funds. (Data source: Wind)

In terms of shares, E Fund Innovative Drug ETF experienced a significant increase of 23.00 million units in share count over the past two weeks, with the new share increase ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest capital inflow and outflow for E Fund Innovative Drug ETF were flat. Over a longer time frame, within the past 10 trading days, it attracted a total of 32.0681 million yuan in net inflow. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of E Fund Innovative Drug ETF reached 3.9035 million yuan, with the latest margin financing balance standing at 38.5900 million yuan. (Data source: Wind)

As of June 15, the net value of E Fund Innovative Drug ETF rose by 16.43% over the past two years, ranking first among comparable funds. From the perspective of return capability, as of June 15, 2026, since its inception, the ETF achieved a highest single-month return of 22.96%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 33.43%, and an average return of 5.62% in up months. As of June 15, 2026, the ETF's annualized excess return over its benchmark for the past two years was 3.21%, ranking 1/7 among comparable funds.

In terms of drawdown, as of June 15, 2026, E Fund Innovative Drug ETF recorded a drawdown of 0.16% relative to its benchmark since the beginning of the year.

In terms of fees, E Fund Innovative Drug ETF has a management fee rate of 0.15% and a custodian fee rate of 0.05%, the lowest fee rates among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which E Fund Innovative Drug ETF tracks, is only 41.54 times, standing at the 2.64% percentile over the past year. This means the valuation is lower than over 97.36% of the time in the past year, placing it at a historical low.

E Fund Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.